Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Delays look like the best-case scenario for teplizumab
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Clinical trial delays become reality as Covid-19 risk spreads
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Upcoming events – Reneuron’s conference data and Provention takes on Crohn’s
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
ADA 2019 – Provention claims success where Lilly failed
The company’s teplizumab delays development of type 1 diabetes, but Lilly’s failure with the same project nine years earlier casts a long shadow.
